GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
GRAIL, a healthcare company focused on early cancer detection, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will present on September 4, 2024, at 3:20 p.m. ET. Investors and interested parties can access both live and replay webcasts of the presentation through GRAIL's investor relations website at investors.grail.com. The webcast will remain available for replay for at least 30 days after the event, providing an opportunity for those unable to attend live to catch up on GRAIL's latest updates and insights.
GRAIL, un'azienda attiva nel settore sanitario specializzata nella diagnosi precoce del cancro, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley. La direzione dell'azienda presenterà il 4 settembre 2024 alle 15:20 ET. Investitori e parti interessate possono accedere sia alla diretta che alle registrazioni della presentazione tramite il sito web delle relazioni con gli investitori di GRAIL all'indirizzo investors.grail.com. La registrazione resterà disponibile per la consultazione per almeno 30 giorni dopo l'evento, offrendo un'opportunità a coloro che non possono partecipare in diretta di recuperare gli ultimi aggiornamenti e approfondimenti di GRAIL.
GRAIL, una empresa de atención médica enfocada en la detección temprana del cáncer, anunció su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. La dirección de la empresa hará una presentación el 4 de septiembre de 2024 a las 3:20 p.m. ET. Inversores y partes interesadas pueden acceder tanto a las transmisiones en vivo como a las grabaciones de la presentación a través del sitio web de relaciones con inversores de GRAIL en investors.grail.com. La grabación estará disponible para su reproducción durante al menos 30 días después del evento, proporcionando una oportunidad para aquellos que no pueden asistir en vivo para ponerse al día con las últimas actualizaciones e información de GRAIL.
그레일(GRAIL), 조기 암 검진에 집중하는 헬스케어 회사가 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 4일 오후 3시 20분 ET에 발표를 진행할 예정입니다. 투자자와 관심 있는 분들은 live 및 재생 웹캐스트를 GRAIL의 투자자 관계 웹사이트 investors.grail.com에서 이용할 수 있습니다. 웹캐스트는 이벤트 이후 최소 30일 동안 재생 가능하므로, 현장에 참석할 수 없는 분들도 GRAIL의 최신 업데이트와 통찰력을 확인할 기회를 제공받습니다.
GRAIL, une entreprise de santé spécialisée dans la détection précoce du cancer, a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. La direction de l'entreprise fera une présentation le 4 septembre 2024 à 15h20 ET. Les investisseurs et les parties intéressées peuvent accéder à la fois aux webcasts en direct et aux rediffusions de la présentation via le site Web des relations avec les investisseurs de GRAIL à investors.grail.com. Le webcast sera disponible pour rediffusion pendant au moins 30 jours après l'événement, offrant ainsi la possibilité à ceux qui ne peuvent pas assister en direct de se mettre à jour sur les dernières nouvelles et analyses de GRAIL.
GRAIL, ein im Gesundheitswesen tätiges Unternehmen, das sich auf die frühe Krebsfrüherkennung konzentriert, gab seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley bekannt. Das Management des Unternehmens wird am 4. September 2024 um 15:20 Uhr ET präsentieren. Investoren und Interessierte können sowohl auf die Live- als auch auf die Wiederholungs-Webcasts der Präsentation über die Investor-Relations-Website von GRAIL unter investors.grail.com zugreifen. Der Webcast wird für mindestens 30 Tage nach der Veranstaltung zur Verfügung stehen, was eine Gelegenheit für diejenigen bietet, die nicht live teilnehmen können, um die neuesten Updates und Einblicke von GRAIL nachzuholen.
- None.
- None.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference-302227805.html
SOURCE GRAIL, Inc.
FAQ
When is GRAIL (GRAL) presenting at the Morgan Stanley Global Healthcare Conference?
How can investors access GRAIL's (GRAL) presentation at the Morgan Stanley conference?
How long will the webcast of GRAIL's (GRAL) Morgan Stanley conference presentation be available?
What is the main focus of GRAIL (GRAL) as a healthcare company?
